KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop

Area of Science:

• Molecular Biology
• Cancer Research
• Oncology

Background:

• KRAS oncoprotein overexpression drives pancreatic ductal adenocarcinoma (PDAC) and other cancers.
• Targeting KRAS is a key therapeutic strategy, but tractable approaches are needed.
• Existing strategies often focus on KRAS gene transcription or canonical signaling pathways.

Purpose of the Study:

• To investigate a novel feed-forward regulatory loop controlling KRAS oncoprotein accumulation.
• To explore the role of translation elongation factor eIF5A and tyrosine kinase PEAK1 in KRAS regulation.
• To evaluate the therapeutic potential of targeting this pathway in KRAS-driven cancers.

Main Methods:

• Mechanistic investigations of the eIF5A-PEAK1 signaling pathway in cancer cells.
• Genetic and pharmacologic perturbation of eIF5A hypusination and glutamine synthesis.
• Preclinical mouse models of PDAC to assess tumor formation and growth inhibition.

Main Results:

• A feed-forward loop involving hypusinated eIF5A and PEAK1 controls KRAS protein synthesis, independent of new KRAS gene transcription and mTOR signaling.
• Perturbing eIF5A-PEAK1 signaling or blocking glutamine synthesis inhibited KRAS, eIF5A, and PEAK1 expression, reducing cancer cell growth, migration, and tumor formation.
• KRAS, eIF5A, and PEAK1 protein levels increased with cancer progression, notably in metastatic populations.

Conclusions:

• The eIF5A-PEAK1 pathway represents a novel mechanism for regulating KRAS oncoprotein levels.
• Targeting eIF5A hypusination, alone or in combination with RAS-ERK pathway inhibitors, offers a promising therapeutic strategy for KRAS-driven cancers like PDAC.
• This study identifies a new avenue for cancer therapy by focusing on post-transcriptional control of oncogenic proteins.